UOC
JSPRW

UBS O'Connor’s Japer Therapeutics Warrants JSPRW Stock Holding History

UBS O'Connor’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-179,723
Closed -$256K – 974
2021
Q3 		$256K Hold
179,723
– – ﹤0.01% 691
2021
Q2 		$208K Hold
179,723
– – ﹤0.01% 716
2021
Q1 		$151K Buy
+179,723
New +$263K ﹤0.01% 705

Other funds holding JSPRW

HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
ICM
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $19.4M AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS O'Connor's JSPRW Position: Q4 2021 in Review

UBS O'Connor sold out of Japer Therapeutics Warrants (JSPRW) in Q4 2021, closing a stake of 179,723 shares — an estimated $256K sold.

UBS O'Connor first reported a position in JSPRW in Q1 2021 and held it in 3 quarters. The position peaked at $256K in Q3 2021. 15 funds tracked by Wall St. Rank hold JSPRW as of Q4 2021.

  • UBS O'Connor reported no remaining Japer Therapeutics Warrants position as of Q4 2021 after selling out during the quarter.
  • UBS O'Connor sold 179,723 Japer Therapeutics Warrants shares in Q4 2021, an estimated $256K.
  • UBS O'Connor first reported a position in Japer Therapeutics Warrants in Q1 2021 and held it in 3 quarters.
  • UBS O'Connor's Japer Therapeutics Warrants position peaked at $256K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.